Boston Scientific Corporation
BSX · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $16,747 | $14,240 | $12,682 | $11,888 |
| % Growth | 17.6% | 12.3% | 6.7% | – |
| Cost of Goods Sold | $6,480 | $5,409 | $4,968 | $4,427 |
| Gross Profit | $10,267 | $8,831 | $7,714 | $7,461 |
| % Margin | 61.3% | 62% | 60.8% | 62.8% |
| R&D Expenses | $1,615 | $1,414 | $1,323 | $1,204 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $5,984 | $5,190 | $4,520 | $4,286 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $33 | $46 | $47 | $49 |
| Operating Expenses | $7,632 | $6,650 | $5,890 | $5,539 |
| Operating Income | $2,635 | $2,181 | $1,824 | $1,922 |
| % Margin | 15.7% | 15.3% | 14.4% | 16.2% |
| Other Income/Exp. Net | -$353 | -$196 | -$683 | -$846 |
| Pre-Tax Income | $2,282 | $1,985 | $1,141 | $1,076 |
| Tax Expense | $436 | $393 | $443 | $36 |
| Net Income | $1,854 | $1,593 | $698 | $1,040 |
| % Margin | 11.1% | 11.2% | 5.5% | 8.7% |
| EPS | 1.26 | 1.081 | 0.449 | 0.693 |
| % Growth | 16.6% | 140.8% | -35.2% | – |
| EPS Diluted | 1.25 | 1.073 | 0.446 | 0.687 |
| Weighted Avg Shares Out | 1,472 | 1,453 | 1,431 | 1,422 |
| Weighted Avg Shares Out Dil | 1,486 | 1,464 | 1,440 | 1,434 |
| Supplemental Information | – | – | – | – |
| Interest Income | $107 | $22 | $10 | $4 |
| Interest Expense | $387 | $272 | $464 | $349 |
| Depreciation & Amortization | $1,269 | $1,196 | $1,136 | $1,093 |
| EBITDA | $3,938 | $3,453 | $2,741 | $2,518 |
| % Margin | 23.5% | 24.2% | 21.6% | 21.2% |